Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Current Investments (2021 - 2025)

Historic Cash & Current Investments for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $827.8 million.

  • Krystal Biotech's Cash & Current Investments rose 3853.85% to $827.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $827.8 million, marking a year-over-year increase of 3853.85%. This contributed to the annual value of $827.8 million for FY2025, which is 3853.85% up from last year.
  • Per Krystal Biotech's latest filing, its Cash & Current Investments stood at $827.8 million for Q4 2025, which was up 3853.85% from $731.1 million recorded in Q3 2025.
  • Krystal Biotech's Cash & Current Investments' 5-year high stood at $827.8 million during Q4 2025, with a 5-year trough of $343.1 million in Q3 2021.
  • In the last 5 years, Krystal Biotech's Cash & Current Investments had a median value of $504.8 million in 2023 and averaged $512.5 million.
  • As far as peak fluctuations go, Krystal Biotech's Cash & Current Investments tumbled by 1938.31% in 2023, and later skyrocketed by 5361.84% in 2024.
  • Quarter analysis of 5 years shows Krystal Biotech's Cash & Current Investments stood at $438.1 million in 2021, then dropped by 13.45% to $379.2 million in 2022, then surged by 40.35% to $532.2 million in 2023, then grew by 12.28% to $597.5 million in 2024, then skyrocketed by 38.54% to $827.8 million in 2025.
  • Its last three reported values are $827.8 million in Q4 2025, $731.1 million for Q3 2025, and $682.0 million during Q2 2025.